Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://www.nature.com/articles/s41392-023-01606-1, but it redirected us to https://www.nature.com/articles/s41392-023-01606-1. The analysis below is for the second page.

Title[redir]:
Targeting ferroptosis opens new avenues for the development of novel therapeutics | Signal Transduction and Targeted Therapy
Description:
Ferroptosis is an iron-dependent form of regulated cell death with distinct characteristics, including altered iron homeostasis, reduced defense against oxidative stress, and abnormal lipid peroxidation. Recent studies have provided compelling evidence supporting the notion that ferroptosis plays a key pathogenic role in many diseases such as various cancer types, neurodegenerative disease, diseases involving tissue and/or organ injury, and inflammatory and infectious diseases. Although the precise regulatory networks that underlie ferroptosis are largely unknown, particularly with respect to the initiation and progression of various diseases, ferroptosis is recognized as a bona fide target for the further development of treatment and prevention strategies. Over the past decade, considerable progress has been made in developing pharmacological agonists and antagonists for the treatment of these ferroptosis-related conditions. Here, we provide a detailed overview of our current knowledge regarding ferroptosis, its pathological roles, and its regulation during disease progression. Focusing on the use of chemical tools that target ferroptosis in preclinical studies, we also summarize recent advances in targeting ferroptosis across the growing spectrum of ferroptosis-associated pathogenic conditions. Finally, we discuss new challenges and opportunities for targeting ferroptosis as a potential strategy for treating ferroptosis-related diseases.

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 80,479,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don’t know how the website earns money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

pubmed, ferroptosis, google, scholar, cas, cancer, cell, central, cells, iron, shown, gpx, death, lipid, disease, pathway, diseases, chem, injury, target, targeting, role, biol, protein, inhibitors, inhibitor, peroxidation, tumor, inhibiting, addition, metabolism, activity, recently, res, clinical, including, drug, mice, studies, damage, glutathione, sci, therapy, gsh, med, nature, treating, cellular, nanoparticles, wang,

Topics {✒️}

cso-ss-cy7-hex/spion/srfn319 crispr/cas9-based gene editing nature portfolio privacy policy advertising akt/gsk-3beta/nrf2 pathway l-g-glutamyl-p-nitroanilide therapeutic index monocyte/macrophage-specific scavenger receptor hmg-coa 3-hydroxy-3-methylglutaryl-coa p62-keap1-nrf2 signaling pathway apoptosis-inducing factor-homologous mitochondrion ferroptosis-focused translational research social media p62-keap1-nrf2 signalling pathway gene editing oncogenic-ras-harboring cancer cells tfr1-specific antibody 3f3-fma fenton-reaction-acceleratable magnetic nanoparticles activating sirt3-sod2/gpx4 pathway hmgcr 3-hydroxy-3-methylglutaryl-coa reductase febs open bio p62-keap1-nrf2 pathway protects ischemia-induced myocardial injury260 reprints /r-induced cerebral injury259 sirt1/nrf2/ho-1/gpx4 pathway ischemia-induced myocardial damage oxalate crystal‒induced models gpx4-knockout fsp1-overexpressing cells hepatic ischemia-reperfusion injury hepatic ischemia/reperfusion injury system xc–-gsh-gpx4 pathway oxalate crystal‒induced inflammation long-chain polyunsaturated bonds chemical tools imaging-guided photodynamic therapy triple-negative breast cancer small-molecule screening identifies opioid-induced delayed cardioprotection oxidant-enriched tumorigenic endothelial lf receptor‒mediated transcytosis 78 methionine/choline-deficient‒induced enzyme cystathionine beta-synthase cell line data encapsulated metal-organic network sudden-onset kidney failure 1-[ethan-1’ol]-2-methyl-3-hydroxypyridin-4 cbs cystathionine beta-synthase /r-induced acute damage

Questions {❓}

  • The future (2023-?
  • What is the most appropriate dose of N-acetylcysteine after massive acetaminophen overdose?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Targeting ferroptosis opens new avenues for the development of novel therapeutics
         description:Ferroptosis is an iron-dependent form of regulated cell death with distinct characteristics, including altered iron homeostasis, reduced defense against oxidative stress, and abnormal lipid peroxidation. Recent studies have provided compelling evidence supporting the notion that ferroptosis plays a key pathogenic role in many diseases such as various cancer types, neurodegenerative disease, diseases involving tissue and/or organ injury, and inflammatory and infectious diseases. Although the precise regulatory networks that underlie ferroptosis are largely unknown, particularly with respect to the initiation and progression of various diseases, ferroptosis is recognized as a bona fide target for the further development of treatment and prevention strategies. Over the past decade, considerable progress has been made in developing pharmacological agonists and antagonists for the treatment of these ferroptosis-related conditions. Here, we provide a detailed overview of our current knowledge regarding ferroptosis, its pathological roles, and its regulation during disease progression. Focusing on the use of chemical tools that target ferroptosis in preclinical studies, we also summarize recent advances in targeting ferroptosis across the growing spectrum of ferroptosis-associated pathogenic conditions. Finally, we discuss new challenges and opportunities for targeting ferroptosis as a potential strategy for treating ferroptosis-related diseases.
         datePublished:2023-09-21T00:00:00Z
         dateModified:2023-09-21T00:00:00Z
         pageStart:1
         pageEnd:30
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1038/s41392-023-01606-1
         keywords:
            Biologics
            Cell biology
            Medicine/Public Health
            general
            Internal Medicine
            Cancer Research
            Cell Biology
            Pathology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig6_HTML.png
         isPartOf:
            name:Signal Transduction and Targeted Therapy
            issn:
               2059-3635
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Shumin Sun
               affiliation:
                     name:Zhejiang University School of Medicine
                     address:
                        name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jie Shen
               affiliation:
                     name:Zhejiang University School of Medicine
                     address:
                        name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jianwei Jiang
               affiliation:
                     name:Zhejiang University School of Medicine
                     address:
                        name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Fudi Wang
               url:http://orcid.org/0000-0001-8730-0003
               affiliation:
                     name:Zhejiang University School of Medicine
                     address:
                        name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Junxia Min
               url:http://orcid.org/0000-0001-8099-6327
               affiliation:
                     name:Zhejiang University School of Medicine
                     address:
                        name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Targeting ferroptosis opens new avenues for the development of novel therapeutics
      description:Ferroptosis is an iron-dependent form of regulated cell death with distinct characteristics, including altered iron homeostasis, reduced defense against oxidative stress, and abnormal lipid peroxidation. Recent studies have provided compelling evidence supporting the notion that ferroptosis plays a key pathogenic role in many diseases such as various cancer types, neurodegenerative disease, diseases involving tissue and/or organ injury, and inflammatory and infectious diseases. Although the precise regulatory networks that underlie ferroptosis are largely unknown, particularly with respect to the initiation and progression of various diseases, ferroptosis is recognized as a bona fide target for the further development of treatment and prevention strategies. Over the past decade, considerable progress has been made in developing pharmacological agonists and antagonists for the treatment of these ferroptosis-related conditions. Here, we provide a detailed overview of our current knowledge regarding ferroptosis, its pathological roles, and its regulation during disease progression. Focusing on the use of chemical tools that target ferroptosis in preclinical studies, we also summarize recent advances in targeting ferroptosis across the growing spectrum of ferroptosis-associated pathogenic conditions. Finally, we discuss new challenges and opportunities for targeting ferroptosis as a potential strategy for treating ferroptosis-related diseases.
      datePublished:2023-09-21T00:00:00Z
      dateModified:2023-09-21T00:00:00Z
      pageStart:1
      pageEnd:30
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1038/s41392-023-01606-1
      keywords:
         Biologics
         Cell biology
         Medicine/Public Health
         general
         Internal Medicine
         Cancer Research
         Cell Biology
         Pathology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-023-01606-1/MediaObjects/41392_2023_1606_Fig6_HTML.png
      isPartOf:
         name:Signal Transduction and Targeted Therapy
         issn:
            2059-3635
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Shumin Sun
            affiliation:
                  name:Zhejiang University School of Medicine
                  address:
                     name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jie Shen
            affiliation:
                  name:Zhejiang University School of Medicine
                  address:
                     name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jianwei Jiang
            affiliation:
                  name:Zhejiang University School of Medicine
                  address:
                     name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Fudi Wang
            url:http://orcid.org/0000-0001-8730-0003
            affiliation:
                  name:Zhejiang University School of Medicine
                  address:
                     name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Junxia Min
            url:http://orcid.org/0000-0001-8099-6327
            affiliation:
                  name:Zhejiang University School of Medicine
                  address:
                     name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Signal Transduction and Targeted Therapy
      issn:
         2059-3635
      volumeNumber:8
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Zhejiang University School of Medicine
      address:
         name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
         type:PostalAddress
      name:Zhejiang University School of Medicine
      address:
         name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
         type:PostalAddress
      name:Zhejiang University School of Medicine
      address:
         name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
         type:PostalAddress
      name:Zhejiang University School of Medicine
      address:
         name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
         type:PostalAddress
      name:Zhejiang University School of Medicine
      address:
         name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Shumin Sun
      affiliation:
            name:Zhejiang University School of Medicine
            address:
               name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
               type:PostalAddress
            type:Organization
      name:Jie Shen
      affiliation:
            name:Zhejiang University School of Medicine
            address:
               name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
               type:PostalAddress
            type:Organization
      name:Jianwei Jiang
      affiliation:
            name:Zhejiang University School of Medicine
            address:
               name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
               type:PostalAddress
            type:Organization
      name:Fudi Wang
      url:http://orcid.org/0000-0001-8730-0003
      affiliation:
            name:Zhejiang University School of Medicine
            address:
               name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Junxia Min
      url:http://orcid.org/0000-0001-8099-6327
      affiliation:
            name:Zhejiang University School of Medicine
            address:
               name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
      name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
      name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
      name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China
      name:The First Affiliated Hospital, Institute of Translational Medicine, The Second Affiliated Hospital, School of Public Health, Cancer Center, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China

External Links {🔗}(1720)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Particles.js
  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

7.26s.